Cytogenetic and molecular evolution
| Date . | Disease status . | Treatment . | Cytogenetics . | FISH . | RT-PCR BCR-ABL/ABL ratio (%) . |
|---|---|---|---|---|---|
| Oct 1997 | Chronic phase | Allo-SCT | 100% XY t(9;22) | ND | 90 |
| Sep 1998 | Molecular relapse | DLI | 100% XX | 100% XX | 10 |
| Sep 1999 | Cytogenetic relapse | DLI | 92% XY t(9;22)* | ND | 80 |
| Dec 1999 | Hematologic relapse | DLI (+ IL-2) | 100% XY t(9;22)* | ND | ND |
| Aug 2000 | Hematologic relapse | Starts STI571 | 100% XY t(9;22)* | 100% XY | ND |
| Nov 2000 | Remission | STI571 | 97% XX | ND | ND |
| Feb 2001 | Remission | STI571 | 97% XX | 100% XX | 1 |
| May 2001 | Remission | STI571 | 100% XX | 100% XX | 0.3 |
| Aug 2001 | Remission | STI571 | 100% XX | 100% XX | 0.2 |
| Date . | Disease status . | Treatment . | Cytogenetics . | FISH . | RT-PCR BCR-ABL/ABL ratio (%) . |
|---|---|---|---|---|---|
| Oct 1997 | Chronic phase | Allo-SCT | 100% XY t(9;22) | ND | 90 |
| Sep 1998 | Molecular relapse | DLI | 100% XX | 100% XX | 10 |
| Sep 1999 | Cytogenetic relapse | DLI | 92% XY t(9;22)* | ND | 80 |
| Dec 1999 | Hematologic relapse | DLI (+ IL-2) | 100% XY t(9;22)* | ND | ND |
| Aug 2000 | Hematologic relapse | Starts STI571 | 100% XY t(9;22)* | 100% XY | ND |
| Nov 2000 | Remission | STI571 | 97% XX | ND | ND |
| Feb 2001 | Remission | STI571 | 97% XX | 100% XX | 1 |
| May 2001 | Remission | STI571 | 100% XX | 100% XX | 0.3 |
| Aug 2001 | Remission | STI571 | 100% XX | 100% XX | 0.2 |
FISH indicates fluorescence in situ hybridization; STI571, imatinib mesylate; ND, not done.
Plus del(13q), t(5;12), der(6), der(8), and nonclonal rearrangements.